A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

AN OPEN-LABEL, PHASE 4, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE INDOCTION OF RESPONSE AND REMISSION OF VEDOLIZUMAB DUAL TARGETED THERAPY WITH TOFACITINIB IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Intervention/treatment:
ENTYVIO / XELJANZ
Medical condition:
ULCERATIVE COLITIS
Protocol code:
VEDOLIZUMAB-4054
Control number:
281409
Status:
Recruiting
Approved:
January 10, 2024
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT06095128
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Takeda Contact
Role
CONTACT
Phone:
+1-877-825-3327
Sponsor
TAKEDA DEVELOPMENT CENTER AMERICAS INC

Locations

Ontario

ABP Research Services Corp.
Oakville, Ontario, L6L 5L7
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
1 905-849-7426
Name
Pham Joe
Role
PRINCIPAL_INVESTIGATOR
Barrie GI Associates Inc.
Barrie, Ontario, L4M 7G1
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
705-721-3344
Name
Rima Petroniene
Role
PRINCIPAL_INVESTIGATOR
London Health Sciences Centre
London, Ontario, N6A 5A5
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
519-685-8500
Name
Vipul Jairath
Role
PRINCIPAL_INVESTIGATOR
Taunton Surgical Centre
Oshawa, Ontario, L1J 0C7
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
905-723-8551
Name
Daniel Green
Role
PRINCIPAL_INVESTIGATOR
Toronto Digestive Disease Associates (TDDA) Inc.
Vaughan, Ontario, L4L 4Y7
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
416-650-0017
Name
Lee Roth
Role
PRINCIPAL_INVESTIGATOR
Toronto Immune and Digestive Health Institute Inc. (TIDHI)
North York, Ontario, M6A3B4
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
16478122113
Name
Mark Silverberg
Role
PRINCIPAL_INVESTIGATOR
Viable Clinical Research - North Bay
North Bay, Ontario, P1B 2H3
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
(705) 476-7737
Name
Stephane Gauthier
Role
PRINCIPAL_INVESTIGATOR
West GTA Endoscopy Inc.
Mississauga, Ontario, L5M 7N4
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
905-823-0223
Name
Yusuf Arif
Role
PRINCIPAL_INVESTIGATOR

Quebec

The Research Institute of the McGill University Health Centre
Montreal, Quebec, H3G 1A4
RECRUITING
Name
Site Contact
Role
CONTACT
Phone:
514-934-1934
Name
Talat Bessissow
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources